Comparison of the Effects of Myristoylated and Transactivating Peptide (TAT) Conjugated Mitochondrial Fission Peptide Inhibitor (P110) in Myocardial Ischemia/Reperfusion (I/R) Injury

Authors

Israel Benjamin, Philadelphia College of Osteopathic Medicine
Jonathan Vu, Philadelphia College of Osteopathic Medicine
Christina Lipscombe, Philadelphia College of Osteopathic Medicine
Devon Stutzman, Philadelphia College of Osteopathic Medicine
Carly Schmigdall, Philadelphia College of Osteopathic Medicine
Harsh Patel, Philadelphia College of Osteopathic Medicine
Qian Chen, Philadelphia College of Osteopathic MedicineFollow
Cathy J. Hatcher, Philadelphia College of Osteopathic MedicineFollow
Robert Barsotti, Philadelphia College of Osteopathic MedicineFollow
Lindon H. Young, Philadelphia College of Osteopathic MedicineFollow

Document Type

Article

Publication Date

2015

Publication Title

Proceedings of the 24th Annual American Peptide Symposium

Comments

This article was published in Proceedings of the 24th American Peptide Symposium .

Copyright © 2015 APS.

Recommended Citation

Benjamin, Israel; Vu, Jonathan; Lipscombe, Christina; Stutzman, Devon; Schmigdall, Carly; Patel, Harsh; Chen, Qian; Hatcher, Cathy J.; Barsotti, Robert; and Young, Lindon H., "Comparison of the Effects of Myristoylated and Transactivating Peptide (TAT) Conjugated Mitochondrial Fission Peptide Inhibitor (P110) in Myocardial Ischemia/Reperfusion (I/R) Injury" (2015). PCOM Scholarly Works. 1654.
https://digitalcommons.pcom.edu/scholarly_papers/1654